All News
EULAR 2022 – Day 3 Report
By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
Read Article
#OP0286 #EULAR2022 With no licensed therapy, we need a better and responsive outcome measure. Using data-driven method, SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR) has been developed. This will be evaluated in NECESSITY RCTs across Europe @RheumNow https://t.co/U5Aj6bwWBy
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Top Influencers of #EULAR2022: @RichardPAConway @RheumNow @eular_org @EMEUNET @rheum_cat @ARD_BMJ @ProftDr More 📊 https://t.co/fUfohEZAoX
Symplur Hashtags healthhashtags ( View Tweet)
#ClinicalPearl? #METEOR is a multi-country ~40K database of #rheumatoid arthritis. @eular_org #EULAR2022- found YOUNGER age of onset of RA close to equator, opposite to low Vitamin D if more NORTH /less sun and MORE #multiple #sclerosis. ?From low age at equator OP0035 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Padoan et al. Cancer increased in EGPA. SIR 1.99 (1.22-3.08) all cancer, 1.86 (0.98-2.75) exc. NMSC. Higher ANCA+ 2.42 (1.30-4.16) and CYC treated 2.42 (1.11-4.60). 60% within years 1-5 post diagnosis @RheumNow #EULAR2022 POS0838 https://t.co/9GDLsBknO6
Richard Conway RichardPAConway ( View Tweet)
Frisell et al. Safety b/tsDMARDs from 10 years ARTIS. There is a mass of interesting data here, look at that figure! Higher rates of discontinuation due to AEs for tofa, bari, sari, rituximab. May be explained by chanelling and residual confounding @RheumNow #EULAR2022 POS0637 https://t.co/KrspU6c9Cs
Richard Conway RichardPAConway ( View Tweet)
Dr Gossec et al. Multidomain indices show consistent benefit when applied to IL23i guselkumab COSMOS trial. I like MDA (because its simple and so am I) so showing that. But same benefits seen in DAPSA, PASDAS, mCPDAI, GRACE, PsARC. @RheumNow #EULAR2022 POS1038 https://t.co/EU2VHpEGc3
Richard Conway RichardPAConway ( View Tweet)
Characteristics assoc outcomes PsO/PsA/axSpA @pedrommcmachado @rheum_covid bDMARDS, NSAIDs assoc better outcomes. Usually culprits assoc worse outcomes (age, CVD etc), and also disease activity and steroids @RheumNow #EULAR2022 OP0249 https://t.co/siLdQVj2jb https://t.co/BmdwspDhsG
Links:
Richard Conway RichardPAConway ( View Tweet)
What drives residual pain improvement in #JAKi treated pts? Dunno but #Baricitinib and #Sarilimab showed better pain decrease vs placebo and #Adalimumab. #OP0052 showed both #Tofacitinib & Adalimumab reduced pain more than placebo in PsA & RA if in remission @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Mease et al. IL23i guselkumab on axial outcomes in PsA at 2 years in DISCOVER-2. Guselkumab improves BASDAI, mBASDAI, spinal pain, ASDAS to week 100. Still trying to get my head around this seeming to work for PsA spinal disease but not axSpA @RheumNow #EULAR2022 POS1037 https://t.co/LZgXEl6Ohl
Richard Conway RichardPAConway ( View Tweet)
Babies! Safety and Outcomes Data on Pregnancies
#EULAR2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye...
https://t.co/ulQIo2gdlO https://t.co/dpoMd5Wbah
Links:
Dr. John Cush RheumNow ( View Tweet)
Getting Real on PMR
Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022
https://t.co/BCdOTzeOHx https://t.co/VO95uHaKxg
Links:
Dr. John Cush RheumNow ( View Tweet)
Full circle. I met Prof D Isenberg at my first EULAR Congress 10 years ago. He welcomed a strangers request to come for Rheumatology training at UCLH with open arms. A kind, generous soul. My heart is full whenever we meet.❤️ https://t.co/yvwYyDKRD6
Dzifa Dey RheumtoBloom ( View Tweet)
Looks like I’m not the only one who doesn’t let the absence of synovitis stop me from sometimes treating high-risk clinically suspect arthralgias i.e. ‘very early early RA’
The truth comes out in anonymous surveys!
#EULAR2022 @RheumNow https://t.co/BqTLy4HBWR
David Liew drdavidliew ( View Tweet)
A bit late but finally managed to get a proper Danish pastries on Day 3 in 🇩🇰🥳 #EULARpastrychallenge 🥐 #EULAR2022 https://t.co/PhmOd3ylzb
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Interesting stats - over 4400 #EULAR2022 tweets yesterday but only half that number today. #ConferenceFatigue @RheumNow https://t.co/HILdrb5Wkd
TheDaoIndex KDAO2011 ( View Tweet)
#OP0279 #EULAR2022 Let's start with N=5! Promising new therapy CAR T-cell in #lupus. All patients were refractory to various therapies and had active nephritis. Post-treatment, all responded clinically and serologically! Need to go to RCT next @RheumNow https://t.co/RaTlVALQqn
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Difficult to Treat RA (D2TRA): Jacob van Laar
#EULAR2022 Points to consider @RheumNow
1. Consider the diagnosis! Misdiagnosis or mimic?
2. U/s when in doubt
3. Caution in comorbidities (obesity, fm) which can overestimate inflamm markers, disease activity https://t.co/YT9NRv7EA0
Eric Dein ericdeinmd ( View Tweet)
@eular_org Systematic Literature Review #workstatus in #RMDs
vs. general pop.
% manuscrits describing worse outcomes:
-unemployment 67%
-work disability/stop work
91%
-absenteeism 92%
Time to collaborate w/ policy makers to reduce employment gap!
#EULAR2022 @RheumNow
POS0160
Aurelie Najm AurelieRheumo ( View Tweet)
After linking ultra-processed food with developing autoimmune disease in at-risk individuals, we clarified:
What is an ultra-processed food?
has undergone mechanic or enzymatic processing
Not all bread is the same.
Dietary surveys fail on this.
Joao Sabino #EULAR2022 @RheumNow https://t.co/RIRagCe4nd
David Liew drdavidliew ( View Tweet)